This invention relates to the apparatus and methods of endovascular treatment of blood clots obstructing passageways in the circulatory system and particularly the endovascular treatment of pulmonary embolism.
Thromboembolism is the formation in a blood vessel of a clot (thrombus) that breaks loose (embolizes) and is carried by the blood stream to another location in the circulatory system resulting in a clot or obstruction at that new location. For example, a clot may embolize and plug a vessel in the lungs (pulmonary embolism), the brain (stroke), the gastrointestinal tract, the kidneys, or the legs. Thromboembolism is a significant cause of morbidity (disease) and mortality (death), especially in adults. A thromboembolism can be sudden and massive or it may be small and multiple. A thromboembolism can be any size and a thromboembolic event can happen at any time.
When a thrombus forms in the venous circulation of the body it often embolizes to the lungs. Such a thrombus typically embolizes from the veins of the legs, pelvis, or inferior vena cava and travels to the right heart cavities and then into the pulmonary arteries thus resulting in a pulmonary embolism.
A pulmonary embolism results in right heart failure and decreased blood flow through the lungs with subsequent decreased oxygenation of the lungs, heart and the rest of the body. More specifically, when such a thrombus enters the pulmonary arteries, obstruction and spasm of the different arteries of the lung occurs which further decreases blood flow and gaseous exchange through the lung tissue resulting in pulmonary edema. All of these factors decrease the oxygen in the blood in the left heart. As a result, the oxygenated blood supplied by the coronary arteries to the musculature of both the left and right heart is insufficient for proper contractions of the muscle which further decreases the entire oxygenated blood flow to the rest of the body. This often leads to heart dysfunction and specifically right ventricle dysfunction.
This condition is relatively common and has many causes. Some of the more common causes are prolonged inactivity such as bed rest, extended sitting (e.g., lengthy aircraft travel), dehydration, extensive surgery or protracted disease. Almost all of these causes are characterized by the blood of the inferior peripheral major circulatory system coagulating to varying degrees and resulting in permanent drainage problems.
There exist a number of approaches to treating thromboembolism and particularly pulmonary embolism. Some of those approaches include the use of anticoagulants, thrombolytics and endovascular attempts at removal of the emboli from the pulmonary artery. The endovascular attempts often rely on catheterization of the affected vessels and application of chemical or mechanical agents or both to disintegrate the clot. Invasive surgical intervention in which the emboli is removed by accessing the chest cavity, opening the embolized pulmonary artery and/or its branches and removing the clot is also possible.
The prior approaches to treatment, however, are lacking. For example, the use of agents such as anticoagulants and/or thrombolytics to reduce or remove a pulmonary embolism typically takes a prolonged period of time, e.g., hours and even days, before the treatment is effective. In some instances, such agents can cause hemorrhage in a patient. Moreover, the known mechanical devices for removing an embolism are typically highly complex, prone to cause undue trauma to the vessel, and can be difficult and expensive to manufacture.
Lastly, the known treatment methods do not emphasize sufficiently the goal of urgently restoring blood flow through the thrombus once the thrombus has been identified. In other words, the known methods focus primarily and firstly on overall clot reduction and removal instead of first focusing on relief of the acute blockage condition followed then by the goal of clot reduction and removal. Hence, known methods are not providing optimal patient care, particularly as such care relates to treatment of a pulmonary embolism.
In view of the foregoing, several embodiments of the present technology to provide a method and system that initially restores an acceptable level of oxygenated blood to the patient's circulatory system followed by safe and effective removal of the thrombus.
Several embodiments of the present technology treat pulmonary embolism in a minimally invasive manner.
Several embodiments of the present technology can also provide a system that does not cause undue trauma to the vessel.
These and other objects, aspects, features and advantages of which the present technology is capable will be apparent from the following description of embodiments of the present technology, reference being made to the accompanying drawings, in which
Specific embodiments of the present technology will now be described with reference to the accompanying drawings. This present technology may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present technology to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the present technology. In the drawings, like numbers refer to like elements.
Referring to
It will be understood, however, that other access locations into the venous circulatory system of a patient are possible and which are consistent with the present technology. For example, the user can gain access through the jugular vein, the subclavian vein, the brachial vein or any other vein that connects or eventually leads to the superior vena cava. Use of other vessels that are closer to right atrium RA of the patient's heart may be attractive as this will reduce the length of the instruments needed to reach the pulmonary embolism.
Referring to
Referring to
In alternative embodiments, the clot treatment device 402 may be an “over the wire” device, in which case, the wire 401 is a tube or coil having a lumen, and the attachment member 403 and the tip 405 have a hollow central lumen for receiving a guide wire.
In yet a further embodiment, the distal end of the clot treatment device shall have a flexible, atraumatic extension from the device. In an alternative embodiment, the tip 405 is tapered to better penetrate the clot material in the vessel.
In preferred embodiments the clot treatment device 402 of the present technology has a generally cylindrical shape that, during use, creates a flow lumen through the clot material that restores significant blood flow across a clot. The treatment device 402 is not, however, limited to a generally cylindrical shape. For example, the shape can be generally conical, generally concave or generally convex along its axis such that the clot treatment device 402 creates a lumen for restoring the blood flow.
Referring again to
The clot treatment device 402 can self-expand from the undeployed state to the deployed state. For example, the clot treatment device 402 can be a shape-memory material, such as Nitinol, and may be formed as a braid or a stent that is set to have the expanded configuration of the deployed state shown in
Referring to
Referring to
Referring to
The clot treatment device 402 accordingly restores blood flow through the clot 100 immediately or at least quickly after expanding to the deployed state as shown by arrows 407 in
The restoration of blood flow is anticipated to equate with restoration of a substantial portion of the normal blood flow rate for the patient. In less severe. e.g., “sub-massive,” pulmonary embolism patients, the clot treatment device 402 may increase blood flow rate by at least about 50 mllmin, at least about 150 mllmin or between about 100 to 250 mllmin. In severe, e.g., “massive,” pulmonary embolism patients, a larger amount of the pulmonary artery flow is compromised. Hence, in some embodiments, at least about 500 ml/min of blood flow rate may be restored. Moreover, at least a portion of the flow restoration is expected to occur prior to the removal of the clot 100, or any portion thereof.
The restoration of blood flow by the clot treatment device 402 can be achieved in a low pressure environment. For example, the pressure in the target vessel can be less than 60 mmHg and the blood can be venous blood, substantially non-oxygenated blood or low oxygenated blood.
In addition to restoring blood flow, the expansion of the clot treatment device 402 also deforms the clot material by pushing, penetrating and/or otherwise cutting into the clot material. This enhances the subsequent removal of the clot 100 since portions of the clot 100 may be captured and retained (1) between the radially extending portions 406; (2) through the pores of the mesh forming the radially extending portions 406; (3) along the longitudinal cylindrical sections 412 between the radially extending portions 406 of the removal device 402; and (4) within the clot treatment device 402 itself.
As can be understood from the above description and figures, the deployment of the clot treatment device 402 results in an outwardly expanding generally cylindrical force being urged against an inner surface of the clot 100 because the flow restoration portions 412 expand to the first cross-sectional dimension D1 greater than the diameter DL of the delivery catheter lumen 607. This force pushes the clot material outwardly and creates a lumen through which blood flow is restored. As can also be appreciated, the presence of the radially extending capture portions 406 on the clot treatment device 402 causes the outwardly expanding generally cylindrical force to vary in magnitude along the axis of the clot treatment device 402. The force on the clot material may be greater at the locations of the radially extending capture portions 406.
In braided embodiments of the clot treatment device 402, deployment/expansion of the device leads the filaments of the braid to change their angular orientation with respect to the axis of the device. This angular change may improve or enhance adherence of clot material to the clot treatment device 402.
After the clot treatment device 402 has been expanded and blood flow restored, the user then retracts the clot treatment device 402 in a proximal direction as shown in
As further shown in
It will be appreciated that variations in the above-described method are contemplated. For example, in certain circumstances a guide catheter 604 may not be necessary or desirable and the user may choose to use only the delivery catheter 606 for placing and manipulation of the clot treatment device 402. As a further example, the clot may be of such a nature that the user may desire repeat the above-described process, or at least portions of it, in order to more fully remove the clot 100 or clot material.
Referring next to
In certain circumstances, it may be advisable to remove the clot 100 without capturing it in the guide catheter 606 or the collection catheter 612 (if used) and remove the clot 100 by withdrawing the entire system, e.g., guide catheter 605, delivery catheter 604, clot treatment device 402 and collection catheter 612 (if used) simultaneously.
In several embodiments, the expandable portion 614 of the collection catheter 612 is a conical funnel or other tapered member constructed from a mesh, braid or stent structure. Such structure assists in retrieving and containing the clot material in the withdrawal process. In yet further preferred embodiments, the collection catheter 612 contains structural features to assist in the expansion of the expandable portion 614 and to hold the expandable portion 614 open towards the wall of the blood vessel. Such features (not shown) include interwoven support struts, self expanding material (e.g., Nitinol), longitudinal wire supports, stent supports, polymeric webbing, etc.
In another embodiment of the present invention, a vacuum apparatus may be used to aid in the removal of the clot material. Referring to
Referring now to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
The elongated inner member 1020 can be a tube or coil having inner lumen configured to receive the guidewire 602 for over-the-wire or rapid exchange delivery of the expandable member 1010 to the clot. The outer elongated member 1022 can be a tube or coil having a lumen configured to receive the inner elongated member 1020 such that the inner elongated member 1020 and/or the outer elongated member 1022 can move relative to each other along the longitudinal dimension of the clot treatment device 402.
In the operation of the clot treatment device 402 shown in
In the foregoing embodiments, the radially extending capture portions 406 provide more surface area along the device than a device that is uniformly cylindrical. Moreover, the radially extending capture portions 406 extend transversely to the longitudinal dimension of the device to more effectively transfer the axial force as the device is moved axially along the vessel after deployment. Such increased surface area facilitates the treatment and/or retrieval of a much larger portion of the clot 100 than is generally feasible with a uniformly cylindrical device. For example, in a preferred embodiment of the clot treatment device 402, the device will have an external surface area between 1.5× and 6× the surface area of a uniformly cylindrical device of the same general diameter of the cylindrical sections 412. In other preferred embodiments the ratio will be 2× to 4×.
This is advantageous particularly during retraction of the clot treatment device 402 through the clot 100. As shown in
The clot treatment device 402 is intended for use in large vessels, i.e., vessels with a diameter greater than 8 mm. For example, the diameter of the pulmonary arteries typically range from 15 to 30 mm whereas the first branches of the pulmonary arteries typically range from 10 to 15 mm and the secondary and tertiary branches typically range from 5 to 10 mm. At the same time, however, it is important to minimize the size of catheter providing access to the clot 100. Accordingly, the clot treatment device 402 has a large expansion ratio. In a preferred embodiment the expansion ratio from the diameter of the cylindrical sections 412 in the collapsed state to the expanded state will be between 4 and 8. In another preferred embodiment the ratio will be between 5 and 7. The large expansion ratio also enables the formation of a flow channel in the clot 100 that is large, e.g., on the order of 4-8 mm.
The radially extending portions 406, in their fully expanded position are intended to have a size that matches the diameter of the target blood vessel. However, the diameters may be slightly larger than the vessel diameter so to apply greater radial force against the blood vessel (without causing trauma) in those circumstances when it is desirable to improve clot collection. Similarly, in those circumstances where there is a concern of creating trauma on delicate blood vessels, the radially extending portions 406 may have a diameter that is smaller than the vessel diameter. It is contemplated that different sizes of the device 402 will be available for selection by the user for a particular presentation of the patient.
As for the length of the clot treatment device 402, it is known that a typical pulmonary embolism will have a length within the range between about 2 em and 10 em and sometimes between about 1 em and 20 em. Accordingly, in a preferred embodiment, the clot treatment device 402 will have a length that exceeds the length of the embolism so that a portion of the clot treatment device is positioned distal of the clot 100 during expansion.
With regard to the delivery catheter 606, in a preferred embodiment for use with a pulmonary embolism, the size will be around 1 F-6 F. Smaller diameters will pass through the clot 100 more easily. In addition, the delivery catheter 606 may have stiffness characteristics to assist in making sure the delivery catheter 606 passes through the clot in a smooth manner. Such stiffness characteristics include self expanding Nitinol wire braids or stent structures that are contained within the structure of the delivery catheter 606. The delivery catheter 606 also has sufficient flexibility so that it may carry the clot treatment device 402 and still pass through a tortuous vessel path as described above starting with insertion of the delivery catheter 606 in the femoral vein FV.
In some preferred embodiments, the method and device in accordance with the present invention may reduce the Mean Resting Pulmonary Artery Pressure (MRPAP). Upon at least partial relief from the clot 100, MRPAP may be reduced by about 20-50 mmHg to a normal range of 8-20 mmHg. In some embodiments, the reduction in MRPAP may be about 25-50%. In some embodiments, the reduction in MRPAP may be about 15% to 40% and in other embodiments between about 30% and 75%.
Such a reduction in MRPAP can occur in two steps. A first step is when the clot treatment device 402 is first deployed and blood flow is at least partially restored. A second step may be when the clot treatment device 402 is retracted and at least some of the clot 100 is removed from the vessel. A third step may be after the clot treatment device 402 has been removed and the effect of the body's own processes and/or thrombolytic drugs that may have been used before, during or after the procedure take effect upon clot that has been disrupted by the clot treatment device.
The radially expanding guide member 1510 may also be formed by conventional machining, laser cutting, electrical discharge machining (EDM) or other means known in the art to make a fenestrated, mesh or porous structure that can be affixed near the distal end of the shaft 1502. In some embodiments the radially expanding guide member 1510 may self-expand, but in other embodiments it may be actuated by an operator using, for example, electrical or electromechanical means. By having a porous radially expanding guide member 1510, the guide catheter 1500 may be substantially centered within a vessel without blocking a large portion of the flow around the catheter. In some embodiments, the radially expanding guide member 1510 may block less than about 50% of the flow about the catheter and in other embodiments less than about 25% of the flow. When the guide member 1510 is made with a braid of filaments (e.g. wires), it may be formed from a tubular braid. In some embodiments, the tubular braid may be formed with approximately 12 to approximately 144 filaments, or in other embodiments from about 36 to about 96 filaments. The pores as measured by the largest circle that can be inscribed within an opening of the mesh may be between about 0.5 mm and 5 mm.
The CE members 1952 can be disposed about an exterior surface of the device 402. For example, as shown in
As shown in
The CE members can have a single radius of curvature or have regions with different radii or have a complex or changing radius of curvature. For example, as shown in
As shown in
Referring to
Several examples of the present technology are as follows:
1. A device for treating a pulmonary embolism, comprising:
2. The device of example 1 wherein the flow restoration portion and the capture elements comprise an expandable braided material that is heat set to have the deployed state.
3. The device of any of examples 1 and 2 wherein the flow restoration portion and the capture elements are integrally formed from a common braided material.
4. The device of any of examples 1-3, further comprising a plurality of flow restoration portions and the capture elements comprise a series of radially extending capture portions, and wherein the radially extending capture portions are separated from each other by individual flow restoration portions.
5. The device of example 4 wherein the flow restoration portions comprise expandable cylindrical sections and the capture elements comprise radially expandable disk-like capture portions of the braided material.
6. The device of example 1 wherein the flow restoration portion comprises a radially expandable cylindrical braided material and the capture elements comprise protuberances projecting from the flow restoration portion.
7. The device of any of examples 1-6 wherein the flow restoration portion has an expansion ratio from the undeployed state to the deployed state of approximately 1:4 to 1:8.
8. The device of any of examples 1-6 wherein the flow restoration portion has an expansion ratio from the undeployed state to the deployed state of approximately 1:5 to 1:7.
9. The device of any of examples 1-8 wherein the flow restoration portion has a diameter of approximately 4-8 mm in the deployed state to restore blood flow through a pulmonary embolism.
10. The device of any of examples 1-9 wherein the flow restoration portions and the capture elements comprises a self-expanding braided material, and the capture elements comprise capture portions that have a second diameter greater than the first cross-sectional dimension of the flow restoration portions in the deployed state.
11. The device of any of examples 1-3 and 6-9 wherein the flow restoration portion comprises a single expandable braided tube, and the capture elements comprise clot engagement members configured to project from the flow restoration portion in the deployed state.
12. The device of example 11 wherein the clot engagement members comprise arcuate members that form hook-like elements projecting from the flow restoration portion.
13. The device of example 11 wherein the clot engagement members are formed from wires of the expandable braided tube that defines the flow restoration portion.
14. The device of example 11 wherein the clot engagement members are formed from separate wires that project through interstices of the expandable braided tube that defines the flow restoration portion.
15. A pulmonary embolism treatment device, comprising:
16. The pulmonary embolism treatment device of example 15 wherein the expandable member comprises a braided material.
17. The pulmonary embolism treatment device of example 15 wherein the device has a plurality of flow restoration portions and the capture elements are separated by individual flow restoration portions, and wherein (a) the capture elements comprise capture portions formed from a continuous shape-memory braided material heat-set to the deployed state and (b) the capture portions project from the flow restoration portions to a second cross-sectional dimension in the deployed state.
18. The pulmonary embolism treatment device of example 17 wherein the flow restoration portions comprise cylindrical portions and the first cross-sectional dimension comprises a first diameter in the deployed state, and the capture portions comprise disk-like projections having a second diameter greater than the first diameter in the deployed state.
19. The pulmonary embolism treatment device of any of examples 11-18 wherein the flow restoration portion(s) have an expansion ratio from the undeployed state to the deployed state from 1:4 to 1:8.
20. The pulmonary embolism treatment device of any of examples 11-18 wherein the flow restoration portion(s) have an expansion ratio from the undeployed state to the deployed state from 1:5 to 1:7.
21. The pulmonary embolism treatment device of any of examples 11-20 wherein the first elongated member comprises an outer tube and the second elongated member comprises an inner tube within the outer tube.
22. The pulmonary embolism treatment device of any of examples 11-20 wherein the first elongated member comprises an outer tube and the second elongated member comprises a coil within the outer tube.
23. The pulmonary embolism device of any of examples 11-20 wherein the first elongated member comprises an outer coil and the second elongated member comprises an inner coil.
24. The pulmonary embolism treatment device of any of examples 11-23 wherein the flow restoration portion(s) and the capture elements comprise a self-expanding braided material.
25. The pulmonary embolism treatment device of any of examples 11-24 wherein the outer elongated member is configured to slide distally with respect to the inner elongated member to move the expansion member from the undeployed state to the deployed state.
26. The pulmonary embolism treatment device of any of examples 11-25, further comprising a guide catheter having a shaft with a distal end and an expandable guide member at the distal end of the shaft, wherein the shaft has a lumen configured to receive the expandable member in the undeployed state.
27. The pulmonary embolism treatment device of example 26 wherein the expandable guide member comprises radially expandable mesh.
28. The pulmonary embolism treatment device of example 27 wherein the radially expandable mesh comprises a braided material.
29. The pulmonary embolism treatment device of any of examples 26-28 wherein the expandable guide member has a funnel shape.
30. The pulmonary embolism treatment device of any of examples 26-29 wherein at least a portion of the expandable guide member is permeable to allow blood to flow through the expandable guide member when the expandable guide member is expanded.
31. The pulmonary embolism treatment device of any of examples 26-29 wherein the expandable guide member has a non-permeable portion at the distal end of the shaft and a permeable portion extending distally from the non-permeable portion.
32. A pulmonary embolism treatment device, comprising:
33. A method of treating a pulmonary embolism, comprising:
34. The method of example 33 wherein deploying the embolectomy device comprises expanding a plurality of radial extendable capture elements of the embolectomy device.
35. The method of example 34, wherein at least one of the plurality of radial extendable capture elements is expanded distal relative to the pulmonary embolism.
36. The method of example 33, further comprising applying vacuum while withdrawing the embolectomy device.
37. The method of example 36, wherein withdrawing the embolectomy device includes urging the portion of the pulmonary embolism into a funnel catheter.
38. The method of example 37, wherein deploying the embolectomy device comprises expanding the device such that a surface area of the embolectomy device expands within a range of at least 200% to 400% of the surface area of a uniformly cylindrical device.
39. The method of example 33 wherein deploying the embolectomy device comprises expanding the generally cylindrical section by 400% to 800% of its diameter in the undeployed state.
40. The method according to and of examples 33-39 wherein deploying the embolectomy device comprises expanding a braided material into a preset shape having a plurality of radially extending disk-like capture portions that define the capture elements.
Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the exampled invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.
This application is a continuation of U.S. patent application Ser. No. 14/646,358, filed on May 20, 2015 and entitled Methods and Apparatus for Treating Embolism, which is a 371 U.S. national filing of PCT/US2013/071101, filed on Nov. 20, 2013 and entitled Methods and Apparatus for Treating Embolism, which is a continuation-in-part of U.S. patent application Ser. No. 13/843,742, filed on Mar. 15, 2013, now issued as U.S. Pat. No. 8,784,434 and entitled Methods and Apparatus for Treating Embolism, which claims priority to U.S. Provisional Application Ser. No. 61/750,277 filed Jan. 8, 2013 entitled Devices and Methods for Treatment of Vascular Occlusion and U.S. Provisional Application Ser. No. 61/728,775 filed Nov. 20, 2012 entitled Devices and Methods for Treatment of Vascular Occlusion, all of which are hereby incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
2846179 | Monckton | Aug 1958 | A |
3088363 | Sparks | May 1963 | A |
3435826 | Fogarty | Apr 1969 | A |
3892161 | Sokol | Jul 1975 | A |
3923065 | Nozick et al. | Dec 1975 | A |
4030503 | Clark, III | Jun 1977 | A |
4034642 | Iannucci et al. | Jul 1977 | A |
4287808 | Leonard et al. | Sep 1981 | A |
4393872 | Reznik et al. | Jul 1983 | A |
4523738 | Raftis et al. | Jun 1985 | A |
4551862 | Haber | Nov 1985 | A |
4650466 | Luther | Mar 1987 | A |
4873978 | Ginsburg | Oct 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4890611 | Monfort et al. | Jan 1990 | A |
4978341 | Niederhauser | Dec 1990 | A |
5011488 | Ginsburg | Apr 1991 | A |
5059178 | Ya | Oct 1991 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5129910 | Phan et al. | Jul 1992 | A |
5192286 | Phan et al. | Mar 1993 | A |
5192290 | Hilal | Mar 1993 | A |
5360417 | Gravener et al. | Nov 1994 | A |
5370653 | Cragg | Dec 1994 | A |
5476450 | Ruggio | Dec 1995 | A |
5490859 | Mische et al. | Feb 1996 | A |
5591137 | Stevens | Jan 1997 | A |
5746758 | Nordgren et al. | May 1998 | A |
5749858 | Cramer | May 1998 | A |
5766191 | Trerotola | Jun 1998 | A |
5782817 | Franzel et al. | Jul 1998 | A |
5827304 | Hart | Oct 1998 | A |
5868708 | Hart et al. | Feb 1999 | A |
5873866 | Kondo et al. | Feb 1999 | A |
5873882 | Straub et al. | Feb 1999 | A |
5876414 | Straub | Mar 1999 | A |
5882329 | Patterson et al. | Mar 1999 | A |
5972019 | Engelson et al. | Oct 1999 | A |
5974938 | Lloyd | Nov 1999 | A |
5993483 | Gianotti | Nov 1999 | A |
6066149 | Samson et al. | May 2000 | A |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6228060 | Howell | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6423032 | Parodi | Jul 2002 | B2 |
6440148 | Shiber | Aug 2002 | B1 |
6454741 | Muni et al. | Sep 2002 | B1 |
6454775 | Demarais et al. | Sep 2002 | B1 |
6458103 | Albert et al. | Oct 2002 | B1 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6511492 | Rosenbluth et al. | Jan 2003 | B1 |
6514273 | Voss et al. | Feb 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6530939 | Hopkins et al. | Mar 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6551342 | Shen et al. | Apr 2003 | B1 |
6589263 | Hopkins et al. | Jul 2003 | B1 |
6596011 | Johnson et al. | Jul 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6605074 | Zadno-Azizi et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6623460 | Heck | Sep 2003 | B1 |
6635070 | Leeflang et al. | Oct 2003 | B2 |
6645222 | Parodi et al. | Nov 2003 | B1 |
6660013 | Rabiner et al. | Dec 2003 | B2 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6685722 | Rosenbluth et al. | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6699260 | Dubrul et al. | Mar 2004 | B2 |
6755847 | Eskuri | Jun 2004 | B2 |
6767353 | Shiber | Jul 2004 | B1 |
6800080 | Bates | Oct 2004 | B1 |
6824553 | Gene et al. | Nov 2004 | B1 |
6939361 | Kleshinski | Sep 2005 | B1 |
6960222 | Vo et al. | Nov 2005 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7036707 | Aota et al. | May 2006 | B2 |
7041084 | Fojtik | May 2006 | B2 |
7052500 | Bashiri et al. | May 2006 | B2 |
7056328 | Arnott | Jun 2006 | B2 |
7069835 | Nishri et al. | Jul 2006 | B2 |
7094249 | Thomas et al. | Aug 2006 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7220269 | Ansel et al. | May 2007 | B1 |
7232432 | Fulton, III et al. | Jun 2007 | B2 |
7244243 | Lary | Jul 2007 | B2 |
7285126 | Sepetka et al. | Oct 2007 | B2 |
7306618 | Demond et al. | Dec 2007 | B2 |
7320698 | Eskuri | Jan 2008 | B2 |
7323002 | Johnson et al. | Jan 2008 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
7534234 | Fojtik | May 2009 | B2 |
7578830 | Kusleika et al. | Aug 2009 | B2 |
7621870 | Berrada et al. | Nov 2009 | B2 |
7674247 | Fojtik | Mar 2010 | B2 |
7691121 | Rosenbluth et al. | Apr 2010 | B2 |
7695458 | Belley et al. | Apr 2010 | B2 |
7763010 | Evans et al. | Jul 2010 | B2 |
7766934 | Pal et al. | Aug 2010 | B2 |
7905877 | Oscar et al. | Mar 2011 | B1 |
7905896 | Straub | Mar 2011 | B2 |
7938809 | Lampropoulos et al. | May 2011 | B2 |
7938820 | Webster et al. | May 2011 | B2 |
7967790 | Whiting et al. | Jun 2011 | B2 |
7976511 | Fojtik | Jul 2011 | B2 |
7993302 | Hebert et al. | Aug 2011 | B2 |
7993363 | Demond et al. | Aug 2011 | B2 |
8043313 | Krolik et al. | Oct 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8075510 | Aklog et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109962 | Pal | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8197493 | Ferrera et al. | Jun 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8261648 | Marchand et al. | Sep 2012 | B1 |
8267897 | Wells | Sep 2012 | B2 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
8317748 | Fiorella et al. | Nov 2012 | B2 |
8337450 | Fojtik | Dec 2012 | B2 |
RE43902 | Hopkins et al. | Jan 2013 | E |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8361104 | Jones et al. | Jan 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8486105 | Demond et al. | Jul 2013 | B2 |
8491539 | Fojtik | Jul 2013 | B2 |
8512352 | Martin | Aug 2013 | B2 |
8535334 | Martin | Sep 2013 | B2 |
8545526 | Martin et al. | Oct 2013 | B2 |
8568432 | Straub | Oct 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8771289 | Mohiuddin et al. | Jul 2014 | B2 |
8777893 | Malewicz | Jul 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Martin et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8801748 | Martin | Aug 2014 | B2 |
8814927 | Shin et al. | Aug 2014 | B2 |
8820207 | Marchand et al. | Sep 2014 | B2 |
8826791 | Thompson et al. | Sep 2014 | B2 |
8828044 | Aggerholm et al. | Sep 2014 | B2 |
8833224 | Thompson et al. | Sep 2014 | B2 |
8845621 | Fojtik | Sep 2014 | B2 |
8852205 | Brady et al. | Oct 2014 | B2 |
8852226 | Gilson et al. | Oct 2014 | B2 |
8932319 | Martin et al. | Jan 2015 | B2 |
8939991 | Krolik et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
8992504 | Castella et al. | Mar 2015 | B2 |
9005172 | Chung | Apr 2015 | B2 |
9101382 | Krolik et al. | Aug 2015 | B2 |
9149609 | Ansel et al. | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9259237 | Quick et al. | Feb 2016 | B2 |
9283066 | Hopkins et al. | Mar 2016 | B2 |
9408620 | Rosenbluth | Aug 2016 | B2 |
9439664 | Sos | Sep 2016 | B2 |
9439751 | White et al. | Sep 2016 | B2 |
9456834 | Folk | Oct 2016 | B2 |
9463036 | Brady et al. | Oct 2016 | B2 |
9526864 | Quick | Dec 2016 | B2 |
9526865 | Quick | Dec 2016 | B2 |
9566424 | Pessin | Feb 2017 | B2 |
9616213 | Furnish et al. | Apr 2017 | B2 |
9700332 | Marchand et al. | Jul 2017 | B2 |
9717519 | Rosenbluth et al. | Aug 2017 | B2 |
9757137 | Krolik et al. | Sep 2017 | B2 |
9844387 | Marchand et al. | Dec 2017 | B2 |
10004531 | Rosenbluth et al. | Jun 2018 | B2 |
10045790 | Cox et al. | Aug 2018 | B2 |
10098651 | Marchand et al. | Oct 2018 | B2 |
1023840 | Cox et al. | Mar 2019 | A1 |
10335186 | Rosenbluth et al. | Jul 2019 | B2 |
10342571 | Marchand et al. | Jul 2019 | B2 |
10349960 | Quick | Jul 2019 | B2 |
20010004699 | Gittings et al. | Jun 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020111648 | Kusleika et al. | Aug 2002 | A1 |
20020120277 | Hauschild et al. | Aug 2002 | A1 |
20020147458 | Hiblar et al. | Oct 2002 | A1 |
20020156457 | Fisher | Oct 2002 | A1 |
20030114875 | Sjostrom | Jun 2003 | A1 |
20030116731 | Hartley | Jun 2003 | A1 |
20030125663 | Coleman et al. | Jul 2003 | A1 |
20030135230 | Massey et al. | Jul 2003 | A1 |
20030153973 | Soun et al. | Aug 2003 | A1 |
20040039412 | Isshiki et al. | Feb 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050119668 | Teague et al. | Jun 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20060047286 | West | Mar 2006 | A1 |
20060100662 | Daniel et al. | May 2006 | A1 |
20060247500 | Voegele et al. | Nov 2006 | A1 |
20060253145 | Lucas | Nov 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20070112374 | Paul, Jr. et al. | May 2007 | A1 |
20070118165 | DeMello et al. | May 2007 | A1 |
20070161963 | Smalling | Jul 2007 | A1 |
20070179513 | Deutsch | Aug 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski et al. | Aug 2007 | A1 |
20070208361 | Okushi et al. | Sep 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070213753 | Waller | Sep 2007 | A1 |
20070255252 | Mehta | Nov 2007 | A1 |
20080015541 | Rosenbluth et al. | Jan 2008 | A1 |
20080088055 | Ross | Apr 2008 | A1 |
20080157017 | Macatangay et al. | Jul 2008 | A1 |
20080167678 | Morsi | Jul 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234722 | Bonnette et al. | Sep 2008 | A1 |
20080269798 | Ramzipoor et al. | Oct 2008 | A1 |
20080300466 | Gresham | Dec 2008 | A1 |
20090018566 | Escudero et al. | Jan 2009 | A1 |
20090054918 | Henson | Feb 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090160112 | Ostrovsky | Jun 2009 | A1 |
20090163846 | Aklog et al. | Jun 2009 | A1 |
20090182362 | Thompson et al. | Jul 2009 | A1 |
20090281525 | Harding et al. | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20100087850 | Razack | Apr 2010 | A1 |
20100114113 | Dubrul et al. | May 2010 | A1 |
20100121312 | Gielenz et al. | May 2010 | A1 |
20100204712 | Mallaby | Aug 2010 | A1 |
20100249815 | Jantzen et al. | Sep 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20110054405 | Whiting et al. | Mar 2011 | A1 |
20110060212 | Slee et al. | Mar 2011 | A1 |
20110144592 | Wong et al. | Jun 2011 | A1 |
20110152993 | Marchand et al. | Jun 2011 | A1 |
20110190806 | Wittens | Aug 2011 | A1 |
20110213290 | Chin et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110224707 | Miloslavski et al. | Sep 2011 | A1 |
20110251629 | Galdonik et al. | Oct 2011 | A1 |
20110264133 | Hanlon et al. | Oct 2011 | A1 |
20110319917 | David et al. | Dec 2011 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101480 | Ingle et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120143239 | Aklog et al. | Jun 2012 | A1 |
20120165919 | Cox et al. | Jun 2012 | A1 |
20120179181 | Straub et al. | Jul 2012 | A1 |
20120232655 | Lorrison et al. | Sep 2012 | A1 |
20120271231 | Agrawal | Oct 2012 | A1 |
20120310166 | Huff | Dec 2012 | A1 |
20130092012 | Marchand et al. | Apr 2013 | A1 |
20130184703 | Brice et al. | Jul 2013 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
20140025048 | Ward | Jan 2014 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150196744 | Aboytes | Jul 2015 | A1 |
20150238207 | Cox et al. | Aug 2015 | A1 |
20150265299 | Cooper et al. | Sep 2015 | A1 |
20150305756 | Rosenbluth et al. | Oct 2015 | A1 |
20150305859 | Eller | Oct 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150360001 | Quick | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20160113666 | Quick et al. | Apr 2016 | A1 |
20160143721 | Rosenbluth et al. | May 2016 | A1 |
20160262790 | Rosenbluth et al. | Sep 2016 | A1 |
20160277276 | Cox et al. | Oct 2016 | A1 |
20170037548 | Lee | Feb 2017 | A1 |
20170058623 | Jaffrey et al. | Mar 2017 | A1 |
20170105745 | Rosenbluth et al. | Apr 2017 | A1 |
20170112514 | Marchand et al. | Apr 2017 | A1 |
20170189041 | Cox et al. | Jul 2017 | A1 |
20170233908 | Kroczynski et al. | Aug 2017 | A1 |
20170265878 | Marchand et al. | Sep 2017 | A1 |
20170325839 | Rosenbluth et al. | Nov 2017 | A1 |
20180092652 | Marchand et al. | Apr 2018 | A1 |
20180105963 | Quick | Apr 2018 | A1 |
20180193043 | Marchand et al. | Jul 2018 | A1 |
20180256178 | Cox et al. | Sep 2018 | A1 |
20180344339 | Cox et al. | Dec 2018 | A1 |
20180361116 | Quick et al. | Dec 2018 | A1 |
20190046219 | Marchand et al. | Feb 2019 | A1 |
20190070401 | Merritt et al. | Mar 2019 | A1 |
20190150959 | Cox et al. | May 2019 | A1 |
20190231373 | Quick | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
102017004383 | Jul 2018 | DE |
6190049 | Jul 1994 | JP |
2001522631 | May 1999 | JP |
2004097807 | Apr 2004 | JP |
2005230132 | Sep 2005 | JP |
2005323702 | Nov 2005 | JP |
2006094876 | Apr 2006 | JP |
2011526820 | Jan 2010 | JP |
WO-1997017889 | May 1997 | WO |
WO-1999044542 | Sep 1999 | WO |
WO-2000053120 | Sep 2000 | WO |
WO-2005046736 | May 2005 | WO |
WO-2006110186 | Oct 2006 | WO |
WO-2007092820 | Aug 2007 | WO |
WO-2009155571 | Dec 2009 | WO |
WO2010002549 | Jan 2010 | WO |
WO-2010010545 | Jan 2010 | WO |
WO-2010023671 | Mar 2010 | WO |
WO-2010049121 | May 2010 | WO |
WO-2010102307 | Sep 2010 | WO |
WO-2011054531 | May 2011 | WO |
WO-2012009675 | Jan 2012 | WO |
WO-2012011097 | Apr 2012 | WO |
WO-2012065748 | May 2012 | WO |
WO2012120490 | Sep 2012 | WO |
WO-2014047650 | Mar 2014 | WO |
WO-2014081892 | May 2014 | WO |
WO-2015006782 | Jan 2015 | WO |
WO-2015061365 | Apr 2015 | WO |
WO2015191646 | Dec 2015 | WO |
WO2017024258 | Feb 2017 | WO |
WO2017070702 | Apr 2017 | WO |
WO2017106877 | Jun 2017 | WO |
WO2018080590 | May 2018 | WO |
WO2019050765 | Mar 2019 | WO |
WO2019075444 | Apr 2019 | WO |
Entry |
---|
International Search Report and Written Opinion for International App. No. PCT/US2018/055780, Date of Filing: Oct. 13, 2018, Applicant: Inceptus Medical LLC., dated Jan. 22, 2019, 8 pages. |
European Patent Application No. 13838945.7, Extended European Search Report, 9 pages, dated Apr. 15, 2016. |
Gibbs, et al., “Temporary Stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience,” British Heart Journal, 1994, 71:372-377,Oct. 12, 1993 6 pgs. |
Goldhaber, S. et al. “Percutaneous Mechanical Thrombectomy for Acute Pulmonary Embolism—A Double-Edged Sword”, American College of CHEST Physicians, Aug. 2007: 132:2, 363-372. |
Goldhaber, S., “Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy”, Journal of Thrombosis and Haemostasis, 2009: 7 (Suppl. 1): 322-327. |
Gupta, S. et al., “Acute Pulmonary Embolism Advances in Treatment,” JAPI, Association of Physicians India, Mar. 2008, vol. 56, 185-191. |
International Search Report and Written Opinion for International App. No. PCT/US13/61470, dated Jan. 17, 2014, 7 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2014/046567, dated Nov. 3, 2014, 13 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2014/061645, dated Jan. 23, 2015, 15 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2015/034987, dated Jun. 9, 2015, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/034987, dated Sep. 17, 2015, 12 pages. |
International Search Report for International App. No. PCT/US13/71101, dated Mar. 31, 2014, 4 pages. |
Konstantinides, S. et al., “Pulmonary embolism hotline 2012—Recent and expected trials”, Thrombosis and Haemostasis, Jan. 9, 2013:33; 43-50. |
Konstantinides, S. et al., “Pulmonary embolism: risk assessment and management”, European Society of Cardiology; European Heart Journal, Sep. 7, 2012:33, 3014-3022. |
Kucher, N. et al., “Percutaneous Catheter Thrombectomy Device for Acute Pulmonary Embolism: In Vitro and in Vivo Testing”, Circulation, Sep. 2005:112:e28-e32. |
Kucher, N., “Catheter Interventions in Massive Pulmonary Embolism”, CardiologyRounds, Mar. 2006 vol. 10, Issue 3, 6 pages. |
Kucher, N. et al., “Management of Massive Pulmonary Embolism”, Radiology, Sep. 2005:236:3 852-858. |
Kucher, N. et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, 2014, 129, pp. 9 pages. |
Kuo, W. et al., “Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques”, Journal of Vascular and Interventional Radiology, Nov. 2009:20:1431-1440. |
Kuo, W. et al., “Catheter-Directed Embolectomy, Fragmentation, and Thrombolysis for the Treatment of Massive Pulmonary Embolism After Failure of Systemic Thrombolysis”, American College of CHEST Physicians 2008: 134:250-254. |
Kuo, W. MD, “Endovascular Therapy for Acute Pulmonary Embolism”, Continuing Medical Education Society of Interventional Radiology (“CME”); Journal of Vascular and Interventional Radiology, Feb. 2012: 23:167-179. |
Lee, L. et al, “Massive pulmonary embolism: review of management strategies with a focus on catheter-based techniques”, Expert Rev. Cardiovasc. Ther. 8(6), 863-873 (2010). |
Liu, S. et al, “Massive Pulmonary Embolism: Treatment with the Rotarex Thrombectomy System”, Cardiovascular Interventional Radiology; 2011: 34:106-113. |
Muller-Hulsbeck, S. et al. “Mechanical Thrombectomy of Major and Massive Pulmonary Embolism with Use of the Amplatz Thrombectomy Device”, Investigative Radiology, Jun. 2001:36:6:317-322. |
Notice of Allowance for U.S. Appl. No. 13/843,742, dated Mar. 12, 2014, 13 pages. |
Notice of Allowance for U.S. Appl. No. 14/288,778, dated Dec. 23, 2014, 12 pages. |
Reekers, J. et al., “Mechanical Thrombectomy for Early Treatment of Massive Pulmonary Embolism”, CardioVascular and Interventional Radiology, 2003: 26:246-250. |
Schmitz-Rode et al., “New Mesh Basket for Percutaneous Removal of Wall-Adherent Thrombi in Dialysis Shunts,” Cardiovasc Intervent Radiol 16:7-10 1993 4 pgs. |
Schmitz-Rode et al., “Temporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism,” Journal of the American College of Cardiology, vol. 48, No. 4, 2006 (5 pgs.). |
Schmitz-Rode, T. et al., “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter”, JACC Journal of the American College of Cardiology, Aug. 2000:36:2:375-380. |
Spiotta, A et al., “Evolution of thrombectomy approaches and devices for acute stroke: a technical review.” J NeuroIntervent Surg 2015, 7, pp. 7 pages. |
Svilaas, T. et al., “Thrombus Aspiration During Primary Percutaneous Coronary Intervention.” The New England Journal of Medicine, 2008, vol. 358, No. 6, 11 pages. |
Tapson, V., “Acute Pulmonary Embolism”, The New England Journal of Medicine, Mar. 6, 2008:358:2037-52. |
The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease.” Stroke, 2009, 40: p. 9 pages. |
Truong et al., “Mechanical Thrombectomy of Iliocaval Thrombosis Using a Protective Expandable Sheath,” Cardiovasc Intervent Radiol27-254-258, 2004, 5 pgs. |
Turk et al., “ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy.” J NeuroIntervent Surg, vol. 6, 2014, 6 pages. |
Uflacker, R., “Interventional Therapy for Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, Feb. 2001: 12:147-164. |
Verma, R., MD et al. “Evaluation of a Newly Developed Percutaneous Thrombectomy Basket Device in Sheep With Central Pulmonary Embolisms”, Investigative Raiology, Oct. 2006, 41, 729-734. |
International Search Report and Written Opinion for International App. No. PCT/US2015/034987 filed Jun. 9, 2015, Applicant: Inceptus Medical, LLC, dated Sep. 17, 2015, 12 pages. |
English translation of Japanese Office Action received for JP Application No. 2016-564210, Applicant: Inceptus Medical, LLC, dated Sep. 4, 2017, 4 pages. |
Australian Exam Report received for AU Application No. 2015274704, Applicant: Inceptus Medical, LLC, dated Sep. 7, 2017, 3 pages. |
European Search Report received for EP Application No. 15805810.7, Applicant: Inceptus Medical, LLC, dated Sep. 4, 2017, 6 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2016/067628 filed Dec. 19, 2016, Applicant: Inari Medical, Inc, dated Apr. 10, 2017, 11 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2017/029696, Date of Filing: Apr. 26, 2017, Applicant: Inari Medical, Inc, dated Sep. 15, 2017, 19 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2016/058536, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc, dated Mar. 13, 2017, 14 pages. |
European Search Report for European Application No. 16876941.2, Date of Filing: Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Jul. 18, 2019, 7 pages. |
Extended European Search Report for European Application No. 16858462.1, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Jun. 3, 2019, 10 pages. |
European First Office Action received for EP Application No. 13838945.7, Applicant: Inari Medical, Inc., dated Oct. 26, 2018, 7 pages. |
International Search Report and Written Opinion for International App. No. PCT/US2018/048786, Date of Filing: Aug. 30, 2018, Applicant: Inari Medical, Inc., dated Dec. 13, 2018, 12 pages. |
Number | Date | Country | |
---|---|---|---|
20180296240 A1 | Oct 2018 | US |
Number | Date | Country | |
---|---|---|---|
61728775 | Nov 2012 | US | |
61750277 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14646358 | US | |
Child | 15949350 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13843742 | Mar 2013 | US |
Child | 14646358 | US |